Achieving Success With Commercial-Scale Manufacturing Of Cell And Gene Therapies
- Understanding the uniqueness of cell and gene production versus traditional biologics products
- How is Sangamo Therapeutics going to handle the challenges ahead related to CGT production?
- Developing a manufacturing strategy with 3 main pillars factoring development needs, capacity requirements, as well as key supply chain drivers
- Addressing areas of improvement, near term and long term. Case studies to be highlighted include:
- Increase viral vector yield and scalability through appropriate expression systems
- Achieve scale in allogeneic cell therapy products
- Streamline cold chain and delivery to patients for gene and cell therapies
- Developing production and supply chain paths for next-gen therapies for rare diseases versus diseases with larger patient populations such as Crohn’s, HIV and MS
- Developing the next wave of manufacturing leaders to handle the growth in the industry